The G‐to‐A mutation in the cancer‐associated variant of pri‐miR‐30c‐1 leads to a change in the pri‐miR‐30c‐1 structure enabling SRSF3 binding (Fernandez et al, 2017). This evidence concerns the gene SRSF3 and cancer.